A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

✍ Scribed by Richardson, P. G.; Xie, W.; Jagannath, S.; Jakubowiak, A.; Lonial, S.; Raje, N. S.; Alsina, M.; Ghobrial, I. M.; Schlossman, R. L.; Munshi, N. C.; Mazumder, A.; Vesole, D. H.; Kaufman, J. L.; Colson, K.; McKenney, M.; Lunde, L. E.; Feather, J.; Maglio, M. E.; Warren, D.; Francis, D.; Hideshima, T.; Knight, R.; Esseltine, D.-L.; Mitsiades, C. S.; Weller, E.; Anderson, K. C.

• Book ID: 121700634
• Publisher: American Society of Hematology
• Year: 2014
• Tongue: English
• Weight: 510 KB
• Volume: 123
• Category: Article
• ISSN: 0006-4971
• DOI: 10.1182/blood-2013-07-517276